129 related articles for article (PubMed ID: 11239647)
1. Prognostic value of DNA quantification in early epithelial ovarian carcinoma.
Valverde JJ; Martin M; García-Asenjo JA; Casado A; Vidart JA; Díaz-Rubio E
Obstet Gynecol; 2001 Mar; 97(3):409-16. PubMed ID: 11239647
[TBL] [Abstract][Full Text] [Related]
2. Prognostic importance of DNA ploidy and p53 in early stages of epithelial ovarian carcinoma.
Skirnisdóttir I; Sorbe B; Karlsson M; Seidal T
Int J Oncol; 2001 Dec; 19(6):1295-302. PubMed ID: 11713603
[TBL] [Abstract][Full Text] [Related]
3. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):54-61. PubMed ID: 9454661
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of KI67, p53, human epithelial growth factor receptor 2, topoisomerase IIalpha, epidermal growth factor receptor, and nm23 expression of ovarian carcinomas and disseminated tumor cells in the bone marrow.
Schindlbeck C; Hantschmann P; Zerzer M; Jahns B; Rjosk D; Janni W; Rack B; Sommer H; Friese K
Int J Gynecol Cancer; 2007; 17(5):1047-55. PubMed ID: 17433065
[TBL] [Abstract][Full Text] [Related]
5. Clinical value of morphometric and DNA flow cytometric variables as independent predictors of survival in epithelial ovarian carcinoma: a 5-year follow-up study.
Veerman MM; van der Wurff AA; van de Water M; Kruitwagen RF; Feijen HW; Vos MC
Int J Gynecol Pathol; 2009 Sep; 28(5):432-41. PubMed ID: 19696612
[TBL] [Abstract][Full Text] [Related]
6. Malignant mixed Müllerian tumors of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 44 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Sullivan S; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):18-24. PubMed ID: 9454654
[TBL] [Abstract][Full Text] [Related]
7. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
[TBL] [Abstract][Full Text] [Related]
8. A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging.
Skírnisdóttir I; Seidal T; Sorbe B
Int J Gynecol Cancer; 2004; 14(2):259-70. PubMed ID: 15086725
[TBL] [Abstract][Full Text] [Related]
9. The relationship between mutant p53 gene, DNA contents and conventional clinicopathological prognostic variables in cases with endometrial carcinoma.
Osmanağaoğlu MA; Kadioğlu S; Osmanağaoğlu S; Bozkaya H; Reis A; Tekelioğlu Y
Eur J Gynaecol Oncol; 2005; 26(1):64-70. PubMed ID: 15755004
[TBL] [Abstract][Full Text] [Related]
10. [Prognosis value of p53, C-erB-2 and Ki67 proteins in ovarian carcinoma].
Frutuoso C; Silva MR; Amaral N; Martins I; De Oliveira C; De Oliveira HM
Acta Med Port; 2001; 14(3):277-83. PubMed ID: 11552325
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of overexpression of p53 in human ovarian carcinoma patients receiving cisplatin.
Nakayama K; Takebayashi Y; Nakayama S; Hata K; Fujiwaki R; Fukumoto M; Miyazaki K
Cancer Lett; 2003 Mar; 192(2):227-35. PubMed ID: 12668287
[TBL] [Abstract][Full Text] [Related]
12. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas.
van der Zee AG; Hollema H; Suurmeijer AJ; Krans M; Sluiter WJ; Willemse PH; Aalders JG; de Vries EG
J Clin Oncol; 1995 Jan; 13(1):70-8. PubMed ID: 7799045
[TBL] [Abstract][Full Text] [Related]
13. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma.
Klemi PJ; Pylkkänen L; Kiilholma P; Kurvinen K; Joensuu H
Cancer; 1995 Oct; 76(7):1201-8. PubMed ID: 8630898
[TBL] [Abstract][Full Text] [Related]
14. The relationship of the angiogenesis regulators VEGF-A, VEGF-R1 and VEGF-R2 to p53 status and prognostic factors in epithelial ovarian carcinoma in FIGO-stages I-II.
Skirnisdottir I; Seidal T; Åkerud H
Int J Oncol; 2016 Mar; 48(3):998-1006. PubMed ID: 26783205
[TBL] [Abstract][Full Text] [Related]
15. Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival.
Pich A; Margaria E; Chiusa L
J Clin Oncol; 2000 Aug; 18(16):2948-56. PubMed ID: 10944127
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
17. p53 as an independent prognostic marker in lymph node-negative breast cancer patients.
Silvestrini R; Benini E; Daidone MG; Veneroni S; Boracchi P; Cappelletti V; Di Fronzo G; Veronesi U
J Natl Cancer Inst; 1993 Jun; 85(12):965-70. PubMed ID: 8496982
[TBL] [Abstract][Full Text] [Related]
18. p53 and bcl-2 in epithelial ovarian carcinoma: their value as prognostic indicators at a median follow-up of 60 months.
Geisler JP; Geisler HE; Miller GA; Wiemann MC; Zhou Z; Crabtree W
Gynecol Oncol; 2000 May; 77(2):278-82. PubMed ID: 10785478
[TBL] [Abstract][Full Text] [Related]
19. Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer.
Tentes AA; Tripsiannis G; Markakidis SK; Karanikiotis CN; Tzegas G; Georgiadis G; Avgidou K
Eur J Surg Oncol; 2003 Feb; 29(1):69-73. PubMed ID: 12559080
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of p53 accumulation in epithelial ovarian carcinomas.
Berker B; Dunder I; Ensari A; Cengiz SD
Arch Gynecol Obstet; 2002 Aug; 266(4):205-9. PubMed ID: 12192480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
